Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article. A carbonyl compound is useful as a raw material for producing the polymerizable compound. (In the formula (I), Y.sup.1 to Y.sup.8 represent C(O)O, G.sup.1 and G.sup.2 represent a C.sub.1-20 divalent linear aliphatic group, Z.sup.1 and Z.sup.2 represent a C.sub.2-10 alkenyl group that is unsubstituted, or substituted with a halogen atom, A.sup.x represents a C.sub.2-30 organic group with at least one aromatic ring, A.sup.y represents a hydrogen atom or C.sub.1-20 alkyl group, A.sup.1 represents a trivalent aromatic group, A.sup.2 and A.sup.3 represent a C.sub.3-30 divalent alicyclic hydrocarbon group, A.sup.4 and A.sup.5 represent a C.sub.6-30 divalent aromatic group or the like, and Q.sup.1 represents a hydrogen atom.) ##STR00001##

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.